Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.87% | 15.14% | 8.84% | 9.40% | 9.55% |
| Total Other Revenue | 32.99% | 14.73% | 12.58% | 16.88% | 16.87% |
| Total Revenue | 12.38% | 15.13% | 8.93% | 9.60% | 9.71% |
| Cost of Revenue | 4.13% | 28.95% | 3.98% | -5.18% | 3.51% |
| Gross Profit | 15.20% | 11.28% | 10.65% | 15.47% | 12.02% |
| SG&A Expenses | 7.64% | 2.49% | 1.33% | -0.03% | -1.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -60.43% | 123.43% | -97.27% | -107.37% | -26.23% |
| Total Operating Expenses | 0.78% | 66.21% | -15.95% | -2.94% | -2.60% |
| Operating Income | 42.25% | -33.03% | 164.65% | 47.61% | 62.70% |
| Income Before Tax | 40.84% | 38.20% | 118.11% | 43.64% | 24.17% |
| Income Tax Expenses | 80.95% | 278.16% | 412.82% | 47.64% | 19.19% |
| Earnings from Continuing Operations | 34.26% | 6.90% | 110.51% | 42.93% | 25.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | 300.00% | -- | -- |
| Net Income | 34.15% | -66.77% | 81.09% | 40.16% | 17.23% |
| EBIT | 42.25% | -33.03% | 164.65% | 47.61% | 62.70% |
| EBITDA | 31.77% | -41.81% | 88.62% | 30.39% | 31.94% |
| EPS Basic | 39.33% | -65.72% | 85.60% | 43.60% | 21.02% |
| Normalized Basic EPS | 51.54% | -31.08% | 196.55% | 51.63% | 63.69% |
| EPS Diluted | 38.93% | -65.63% | 84.60% | 43.00% | 21.53% |
| Normalized Diluted EPS | 51.60% | -31.16% | 196.18% | 51.54% | 63.50% |
| Average Basic Shares Outstanding | -3.72% | -3.07% | -2.42% | -2.40% | -3.13% |
| Average Diluted Shares Outstanding | -3.75% | -2.95% | -2.31% | -2.34% | -3.02% |
| Dividend Per Share | -- | -1.44% | -- | -- | -- |
| Payout Ratio | -0.24% | -- | -- | -- | -0.39% |